Victoza (liraglutide [rDNA origin] injection
ثبت نشده
چکیده
WARNING: RISK OF THYROID C-CELL TUMORS See full prescribing information for complete boxed warning. • Liraglutide causes thyroid C-cell tumors at clinically relevant exposures in rodents. It is unknown whether Victoza causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans, as human relevance could not be determined by clinical or nonclinical studies (5.1). • Victoza is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) (5.1).
منابع مشابه
Glucagon-like peptide-1 analogues enhance synaptic plasticity in the brain: a link between diabetes and Alzheimer's disease.
Type 2 diabetes has been identified as a risk factor for patients with Alzheimer's disease. Insulin signalling is often impaired in Alzheimer's disease, contributing to the neurodegenerative process. One potential strategy to help prevent this is the normalisation of insulin signalling in the brain. Therefore, the present study was designed to test the effects of novel enzyme-resistant analogue...
متن کاملNEW DRUG APPROVALS Xultophy for Type-2 Diabetes
NEW DRUG APPROVALS Xultophy for Type-2 Diabetes The FDA has approved Xultophy 100/3.6 (insulin degludec 100 units/mL and liraglutide 3.6 mg/mL injection, Novo Nordisk). The product, a once-daily combination of Tresiba (insulin degludec injection) and Victoza (liraglutide injection), is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type-2 diabetes that i...
متن کاملThe nature, significance, and glucagon-like peptide-1 analog treatment of brain insulin resistance in Alzheimer's disease.
Alzheimer's disease (AD) is an age-related neurodegenerative disease leading over the course of decades to the most common form of dementia. Many of its pathologic features and cognitive deficits may be due in part to brain insulin resistance recently demonstrated in the insulin receptor→insulin receptor substrate-1 (IRS-1) signaling pathway. The proximal cause of such resistance in AD dementia...
متن کاملLiraglutide therapy beyond glycemic control: an observational study in Indian patients with type 2 diabetes in real world setting
BACKGROUND Liraglutide is an analog of human glucagon-like peptide-1 (GLP-1) and acts as a GLP-1 receptor agonist. Liraglutide is presently used in the treatment of selected patients with type 2 diabetes mellitus (T2DM). OBJECTIVE To assess efficacy and safety of liraglutide in, overweight and obese Indian patients with T2DM. METHODS A single center, prospective, open-labeled, single-arm, o...
متن کامل